Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386082 | 0.98 | EPHX1 (0.47) | EPHX1TP53HPGDALOX12LMNA | |
| SCHEMBL7290456 | 0.94 | EPHX1 (0.48) | EPHX1TP53HPGDALOX12LMNA | |
| SCHEMBL9255771 | 0.92 | EPHX1 (0.47) | EPHX1TP53HPGDALOX12LMNA | |
| SCHEMBL2047409 | 0.92 | EPHX1 (0.45) | EPHX1TP53HPGDALOX12LMNA | |
| SCHEMBL1493226 | 0.91 | — | — | |
| SCHEMBL9264950 | 0.90 | EPHX1 (0.44) | EPHX1TP53HPGDALOX12LMNA | |
| SCHEMBL29018576 | 0.89 | EPHX1 (0.61) | EPHX1ALDH1A1 | |
| SCHEMBL9256718 | 0.89 | EPHX1 (0.61) | EPHX1ALDH1A1 | |
| SCHEMBL3684347 | 0.89 | EPHX1 (0.60) | EPHX1TP53HPGDALOX12LMNA | |
| SCHEMBL13294283 | 0.89 | EPHX1 (0.60) | EPHX1TP53HPGDALOX12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288340-B1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2416650-B1 | NANOPARTICLE FORMULATIONS AND USES THEROF | ABRAXIS BIOSCIENCE LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570431-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180363018-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Heterocyclic Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-20180289620-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2018-10-11 | — | — | US | disclosed |
| US-10087478-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a nitrogen-containing compound and uses thereof | NOVOZYMES, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-10041101-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2603594-B1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A BICYCLIC COMPOUND AND USES THEREOF | NOVOZYMES INC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2603598-B1 | COMPOSITIONS COMPRISING A GH61 POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A QUINONE COMPOUND AND USES THEREOF | NOVOZYMES INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0269859-B2 | Pyrazolotriazine compounds | OTSUKA PHARMA CO LTD (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5455355-A | Postemergence, preemergence herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-10-03 | — | — | US | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| US-5298632-A | Herbicidal pyrimidine compounds, compositions containing the same and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |
| US-5232897-A | Herbicidal pyrimidine compounds, compositions containing the same and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0457505-A2 | Pyrimidine derivatives and their use as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-4824834-A | TREATING GOUT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0269859-A2 | Pyrazolotriazine compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | PGLS, CEL, PNLIP | EPHX1 1827/4885TP53 3378/4885HPGD 412/4885 |
| US-20180289620-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | EPHX1 2975/4885TP53 21/4885HPGD 1328/4885 |
| US-10570431-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | CEL, VIP, CTRC | EPHX1 1549/4885TP53 4220/4885HPGD 582/4885 |
| US-20180363018-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Heterocyclic Compound And Uses Thereof | CEL, VIP, CTRC | EPHX1 1549/4885TP53 4220/4885HPGD 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.